Abstract: The present invention provides a kit of vectors comprising: (i) a first vector comprising a nucleic acid sequence encoding a first marker component; and (ii) a second vector comprising a nucleic acid sequence encoding a second marker component, wherein, when a cell is transduced with both the first and second vectors, the first and second marker components are expressed by the cell and associate forming a hetero-multimeric marker which is recognised by a cell sorting reagent whereas, when a cell is transduced with either the first or second vector alone, expression of the first or second marker component alone is not recognised by the cell sorting reagent.

Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

Abstract: The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.

Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

Abstract: The present invention relates to chimeric antigen receptor (CAR) which binds the cancer antigen disialoganglioside (GD2). T cells expressing such a CAR are useful in the treatment of cancerous diseases such as neuroblastoma.

Abstract: A method for the production of a graphene layer structure, the method comprising providing a substrate on a heated susceptor in a reaction chamber, the chamber having a plurality of cooled inlets arranged so that, in use, the inlets are distributed across the substrate and have a constant separation from the substrate, rotating the heated susceptor at a rotation rate of at least 300 rpm, supplying a flow comprising a precursor compound through the inlets and into the reaction chamber to thereby decompose the precursor compound and form graphene on the substrate, wherein the inlets are cooled to less than 100° C., preferably 50 to 60° C., and the susceptor is heated to a temperature of at least 50° C. in excess of a decomposition temperature of the precursor, wherein the constant separation is at least 12 cm and preferably from 12 to 20 cm.

Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.

Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.

Abstract: The invention relates to a polypeptide comprising (i) an antigen binding domain (ii) a pre-T-alpha domain ectodomain; and (iii) a trans-membrane domain. The invention also relates to nucleic acids, kits, cells, methods and uses.

Abstract: The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within an intracellular compartment of the cell and comprises a second interaction domain which binds to the first protein interaction domain, wherein binding between the first protein interaction domain and second protein interaction domain is disrupted by the presence of an agent, such that in the absence of the agent, the first protein interaction domain and second protein interaction domain bind and result in retention of the POI within an intracellular compartment; whereas in the presence of the agent, the first protein interaction domain and second protein interaction do not bind and the POI is released from the intracellular compartment and expressed at the cell surface or secreted by the cell.

Abstract: The present invention provides a chimeric receptor which binds a target antigen on a target cell, which comprises: a first antigen binding domain which binds a first epitope of the target antigen, a second antigen binding domain which binds a second epitope of the target antigen; a transmembrane domain; and an intracellular signalling domain.

Abstract: An array of graphene sheets configured to generate electricity from a flow of an ion-containing fluid, wherein the array comprises a plurality of graphene sheets, each graphene sheet comprising first and second electrical contacts, having a surface extending between the first and second electrical contacts for contacting the flow of ion-containing fluid, and wherein each graphene sheet is in electrical contact with at least a further graphene sheet.

Abstract: A chemically-doped graphene transistor comprising a plurality of graphene layers and having a first doped region separated from a second doped region by a third doped region, wherein the first and second doped regions are of an opposite doping type to the third doped region, and wherein each of the first, second and third doped regions each comprise a separate electrical contact.

Abstract: A method for the production of a light-sensitive or light-emitting electronic device, the method comprising forming a light-sensitive or light-emitting device by MOCVD in an MOCVD reaction chamber; and forming a graphene layer structure on the light-sensitive or light-emitting device in the MOCVD reaction chamber; wherein the graphene layer structure comprises from 2 to 10 layers of graphene and wherein the graphene layer structure provides an electrical contact for the device.

Abstract: The present invention provides a chimeric polypeptide comprising: an antigen-binding domain which constitutively binds to an ectodomain of a first chain of a cytokine receptor; a transmembrane domain; and an endodomain from a second chain of the cytokine receptor which chimeric polypeptide, when expressed in a cell, binds to the endogenous first chain of the cytokine receptor causing constitutive cytokine signalling.

Abstract: A method for the production of a graphene layer structure having from 1 to 100 graphene layers, the method comprising providing a substrate having a thermal resistance equal to or greater than that of sapphire, on a heated susceptor in a reaction chamber, the chamber having a plurality of cooled inlets arranged so that, in use, the inlets are distributed across the substrate and have a constant separation from the substrate, supplying a flow comprising a precursor compound through the inlets and into the reaction chamber to thereby decompose the precursor compound and form graphene on the substrate, wherein the inlets are cooled to less than 100° C., preferably 50 to 60° C., and the susceptor is heated to a temperature of at least 50° C. in excess of a decomposition temperature of the precursor, using a laser to selectively ablate graphene from the substrate, wherein the laser has a wavelength in excess of 600 nm and a power of less than 50 Watts.

Abstract: A drive unit for closing a leaf of a door or a window comprises an energy accumulator for providing a closing force for closing the leaf, a damping device which counteracts the closing force and has an electric motor which can be operated as a generator and can be coupled to an actuating element of the drive unit, and a control device for controlling the electric motor. The control device is designed to determine a nominal path curve which indicates a position of the leaf or a closing speed of the leaf in dependence upon time, and to perform the control of the electric motor in order to damp the closing movement of the leaf on the basis of the established target path curve.

Abstract: The present invention relates to an engineered cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) one or more engineered polynucleotides which encode one or more enzymes which are capable of synthesising a therapeutic small molecule when expressed in combination in the cell.

Abstract: A method for the production of graphene on a substrate, the method comprising providing a substrate having Si—OH and/or Si—H moieties on a surface thereof; providing a carbon-containing reagent; contacting the carbon-containing reagent with the surface of the substrate to form a carbon-containing coating attached to the Si—OH and/or Si—H moieties on the surface; depositing one or more metals onto the coated surface to form a metal layer on the coated surface; and heating the substrate under an inert atmosphere to thereby decompose the carbon-containing coating to form a metal-coated graphene layer on the substrate.

Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR wherein the first CAR comprises an activating endodomain and the second CAR comprises an inhibitory endodomain, wherein the inhibitory endodomain comprises C-terminal Src Kinase (CSK).